Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin.
cisplatin resistance
nanomedicine
personalized medicine
polypept(o)ides
rational design
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
pubmed:
6
11
2021
medline:
11
11
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Therapy resistance is the major cause of cancer death. As patients respond heterogeneously, precision/personalized medicine needs to be considered, including the application of nanoparticles (NPs). The success of therapeutic NPs requires to first identify clinically relevant resistance mechanisms and to define key players, followed by a rational design of biocompatible NPs capable to target resistance. Consequently, we employed a tiered experimental pipeline from
Identifiants
pubmed: 34739225
doi: 10.1021/acsnano.1c08632
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Antineoplastic Agents
0
LRRC8A protein, human
0
Membrane Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM